Eli Lilly's Decade-Long Potential

This is a LLY news story, published by Yahoo Finance, that relates primarily to Nvidia news.

LLY news

For more LLY news, you can click here:

more LLY news

Nvidia news

For more Nvidia news, you can click here:

more Nvidia news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

other new Lilly products

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Eli Lilly news, pharmaceutical giants news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

results Eli Lilly

The Motley Fool

•

Health

Where Will Eli Lilly Be in 5 Years?

Summary

Nutrition label

77% Informative

Eli Lilly ( NYSE : LLY ) has been one of the best-performing pharmaceutical giants over the past five years .

Some might argue that it's too late for investors to get in on Eli Lilly , while others could feel that its work in the diabetes and obesity markets still makes it an attractive long-term option.

Eli Lilly has several exciting products in its pipeline, some of which are likely to earn approval in the next 5 years .

Consider when Nvidia made this list on April 15, 2005 ... if you invested $ 1,000 at the time of our recommendation, you’d have $ 765,576 ! Stock Advisor’s total average return is 890% — a market-crushing outperformance compared to 173% for the S&P 500.

VR Score

Informative language

Neutral language

Article tone

semi-formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful